Core Viewpoint - Iovance Biotherapeutics is positioned for significant growth due to its recent product approval and ongoing studies across multiple cancer indications, making it an attractive investment opportunity in the biotech sector [4][10]. Company Overview - Iovance Biotherapeutics has achieved approval for its first product, lifileucel, commercialized as Amtagvi, which targets melanoma that cannot be completely removed by surgery or has metastasized [4]. - The company has a market capitalization of $1.1 billion, with current stock trading at $2.87 [5][6]. Financial Performance - Iovance is not yet profitable, which is typical for biotech firms at this stage, but it reported a 13% increase in revenue to $68 million in the latest quarter [7]. - The stock has shown a price range of $1.64 to $5.88 over the past 52 weeks, indicating volatility and potential for growth [6]. Product and Treatment Efficacy - Amtagvi is a tumor-infiltrating lymphocyte (TIL) treatment that reinvigorates a patient's own TIL to combat cancer cells [6]. - A recent study indicated a 52% objective response rate for Amtagvi in real-world conditions, surpassing the 31% response rate from the clinical trial that led to its accelerated approval [8]. Pipeline and Future Prospects - Iovance is exploring lifileucel for various cancer types and in combination with other treatments, with many trials currently in phase 2, suggesting potential for additional indications soon [9]. - The stock is accessible for investors at under $3, with the potential for significant appreciation if the pipeline proves successful [10].

MPLX has plenty of fuel to continue growing its high-yielding distribution.MPLX (MPLX +1.59%) has been an exceptional income investment over the years. The master limited partnership (MLP) has increased its distribution every year since its formation in 2012. The energy midstream giant currently offers a 7.4% yield, which is several times above the S&P 500's 1.1% dividend yield. The energy company has a strong financial profile and lots of growth coming down the pipeline. As a result, you can buy the MLP (w ...

Nebius and CoreWeave expect monster growth during 2026.Finding stocks that can double in under a year isn't easy. These stocks are often among the hottest on the market and can rapidly rise at any given time. That's the case for both CoreWeave (CRWV 8.22%) and Nebius Group (NBIS 9.12%), as the stocks are up 25% and 17%, respectively, so far in 2026. While some investors may throw in the towel and say they missed these two, I don't think that's necessary. I think both stocks have far more room to run, and co ...

Core Viewpoint - Investors are selling off software stocks due to fears over AI disruption, creating buying opportunities for high-quality businesses [1] Group 1: Company Overview - Doximity, a social feed and software provider for doctors, has seen its stock fall by 66% in the past year, trading close to an all-time low [2] - The company has a market cap of $4.7 billion, with a current stock price of $25.57 and a 52-week range of $23.66 to $76.51 [3] - Doximity began as a social network for medical professionals, allowing them to receive healthcare news and collaborate in a HIPAA-compliant manner [3] Group 2: Business Model - Doximity generates revenue through sponsorships from pharmaceutical companies, with 126 customers spending over $500,000 annually on the platform [4] - Approximately 85% of physicians in the U.S. use Doximity, indicating a strong market presence with little competition [4] Group 3: Growth Potential - The company is expanding into new software tools, including the DoxGPT AI assistant, which is expected to increase user engagement and revenue over time [5] - Revenue growth has been significant, increasing by 448% since March 2020, although it has slowed to 10% year-over-year growth last quarter [7] - Doximity has a strong EBIT margin of 38.5%, indicating best-in-class profitability for a software provider [8] Group 4: Investment Consideration - With a price-to-earnings ratio of 21, Doximity may present a growth stock opportunity amidst the current software market dip driven by AI fears [8]

Core Insights - The Russell 2000 serves as the primary benchmark for small-cap investments, demonstrating strong performance in favorable market conditions [1] - The Vanguard Russell 2000 ETF is highlighted as a cost-effective option for investors, with a low expense ratio of 0.06% and a strategy of holding all stocks in the index [2] - The index comprises approximately 2,000 stocks with market caps ranked between 1,001 and 3,000, including both profitable and unprofitable companies [4] Investment Environment - In bull markets, unprofitable stocks within the Russell 2000 can outperform as investors are more inclined to take risks on speculative companies [5] - Long-term investment cycles benefit from exposure to both high-quality and lower-quality companies, allowing investors to navigate market fluctuations effectively [5][9] Comparison with Other Indexes - The S&P 600 index, which is linked to funds like the iShares Core Small Cap ETF, includes stocks outside the S&P 500 and S&P MidCap 400, but applies a quality screen requiring positive earnings [8] - The S&P 600 is tilted towards larger and higher-quality companies, making it a potentially less risky option compared to the Russell 2000 [8] Conclusion - The Vanguard Russell 2000 ETF is considered the best option for long-term investors due to its comprehensive exposure to the small-cap market and its inclusive nature compared to alternative indexes [9]

Core Viewpoint - Despite high market uncertainty, certain consumer stocks are still considered undervalued and have potential for long-term gains [1] Group 1: Conagra Brands - Conagra Brands has seen a rally since early 2026 but remains down over 20% in the past year due to inflation and changing consumer habits [4] - The company has initiated "Project Catalyst," an AI-based initiative aimed at revamping its core business, though its success remains to be seen [5] - Potential recovery catalysts include selling underperforming brands and acquiring faster-growing ones, alongside a high dividend yield of 7.6% at current prices [6] Group 2: Macy's - Macy's shares have surged nearly 75% over the past six months due to cost-cutting measures, store closures, and targeting affluent customers [7] - The stock trades at a low valuation of 12 times forward earnings compared to competitors like Kohl's at nearly 20 times [8] - The recent bankruptcy of competitor Saks Global may provide Macy's with further opportunities for valuation expansion [9] Group 3: Signet Jewelers - Signet Jewelers' shares have increased by 80% over the past year, driven by successful changes under CEO J.K. Symancyk [10] - The company has embraced lab-grown diamonds and differentiated its retail brands, leading to better-than-expected quarterly results, although earnings growth for the fiscal year is estimated at only 4% [11] - Forecasts for the current fiscal year suggest earnings growth could reach 19.7%, indicating potential for valuation expansion from its current low of 8.5 times forward earnings [12]

Core Viewpoint - Lucid is facing significant challenges in the electric vehicle (EV) market, with its stock down 90% over the past three years due to slowing sales and financial difficulties [1] Company Performance - Lucid's Air sedan is recognized for its impressive technology, holding the world record for the longest distance driven on a single charge at 749 miles [3][4] - The company doubled its vehicle production in 2025 to 18,378 vehicles, with deliveries increasing by 55% to 15,800 [4] - Lucid is developing a more affordable EV model expected to start production later this year, priced around $50,000, which could attract more buyers [5] Financial Challenges - Lucid reported losses of $1 billion in Q3, significantly outpacing its sales of $337 million [6] - The company is likely to continue facing difficulties in reducing losses as it prepares for the launch of its lower-priced EV, which involves high costs [7] Industry Context - The overall EV market is struggling, with U.S. EV sales falling by 36% in Q4 2025 year-over-year [9] - The termination of the EV tax credit program and rising vehicle costs are additional challenges for EV manufacturers [9] - Despite rising vehicle sales, Lucid's total sales remain low, with just over 18,000 vehicles sold in a year, raising concerns about future success [10]

Core Insights - Alphabet is experiencing record revenues and accelerating growth in Google Cloud, driven by aggressive AI investment plans, but there are concerns about whether AI will enhance or undermine growth [1][3] Group 1: Google Search Developments - AI-generated answers are not reducing clicks on Google Search as previously feared; instead, they are driving greater usage and longer, more complex query sessions [4][6] - The Gemini family of large language models is improving ad matching with user intent, reducing irrelevant ads, and enabling monetization of complex queries [6][9] - Alphabet is testing new monetization strategies within AI Mode, including ads below AI-generated responses and a pilot program for exclusive merchant deals [7][8] Group 2: Google Cloud Growth - Google Cloud's revenue grew 48% year over year to $17.7 billion in Q4 2025, with a backlog of nearly $240 billion, up 55% sequentially [9] - The growth of Google Cloud in 2026 will depend on the pace of AI infrastructure expansion, with planned capital expenditures of $175 billion to $185 billion [10][11] - AI-focused Google Cloud customers utilize 1.8 times as many products as non-AI customers, indicating a potential for faster growth and a sticky customer base [11] Group 3: Financial Outlook and Margin Pressure - Rising capital spending may lead to higher depreciation and operating costs, potentially pressuring operating margins and profitability in 2026 [12] - Despite potential margin pressure, efficiency gains from Gemini AI have reduced serving unit costs, and record operating and free cash flow in 2025 provide flexibility for future investments [13]

Core Viewpoint - Seth Klarman's investment strategy indicates a shift from Alphabet to Amazon, highlighting the perceived undervaluation of Amazon amidst market pessimism and strong growth potential in cloud computing and AI services [2][10][12]. Group 1: Alphabet (GOOG) - Klarman initially invested in Alphabet during the COVID-19 pandemic, drawn by its strong free cash flow and dominant market position [4]. - Despite trimming his stake, Klarman sold 41% of his remaining shares in Alphabet last quarter, capitalizing on a significant price increase as the stock's forward P/E ratio rose from around 20 to 30 [5][8]. - Alphabet's recent developments, including lenient antitrust remedies and growth in its core Search and cloud computing businesses, contributed to its stock price surge, making it a top-10 position in Baupost's portfolio [6][8]. Group 2: Amazon (AMZN) - Klarman invested nearly half a billion dollars in Amazon in the fourth quarter, making it the second-largest position in Baupost's portfolio at 9.3% [10]. - Amazon's stock only increased by 5% from the start of 2025, contrasting sharply with Alphabet's 65% rise, which may present a buying opportunity due to its attractive valuation [11][12]. - Amazon Web Services (AWS) showed a 24% year-over-year revenue growth, with expectations for strong earnings acceleration in 2027, despite significant capital expenditures planned for 2026 [14][15].

Core Insights - Oklo and NuScale Power are two innovative companies in the nuclear technology sector, each with unique offerings and market positions [1] Company Overview - Oklo is developing a micro reactor capable of providing clean energy for over a decade without refueling, utilizing both recycled and advanced nuclear fuel for cost efficiency [1] - NuScale Power offers small modular reactors (SMRs) that can be factory-assembled and deployed as needed, having received NRC design certification for one of its reactor designs [4][6] Market Position - Oklo has a market capitalization of $10 billion, while NuScale's market cap is approximately $3.8 billion, indicating a significant valuation difference [2][8] - Oklo's reactors produce about 15 megawatts of electricity, with larger units available, while NuScale's modules generate 50MW or 77MW each, suggesting Oklo's design may appeal to customers needing smaller, continuous power solutions [9] Financial Performance - NuScale has begun generating revenue but is experiencing cash burn and heavy losses, while Oklo currently lacks sales but is diversifying its business through acquisitions [4][6][10] - Oklo's acquisition of Atomic Alchemy allows it to expand into radioisotopes, providing potential near-term revenue [10] Regulatory and Operational Status - NuScale has secured regulatory approval, giving it a first-mover advantage, whereas Oklo is still progressing through the NRC's licensing process, targeting 2027 for commercial operations [4][10]